Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Development and Validation of a UHPLC-DAD Method for the Quantitative Analysis of Major Dihydrochalcone Glucosides from Thonningia sanguinea VAHL.

Pompermaier L, Schwaiger S, Mawunu M, Lautenschlaeger T, Stuppner H.

Planta Med. 2019 Mar 22. doi: 10.1055/a-0877-7255. [Epub ahead of print]

PMID:
30901776
2.

Platelet count correlates with stage and predicts survival in melanoma.

Rachidi S, Kaur M, Lautenschlaeger T, Li Z.

Platelets. 2019 Feb 13:1-5. doi: 10.1080/09537104.2019.1572879. [Epub ahead of print]

PMID:
30759042
3.

Preoperative platelet counts and postoperative outcomes in cancer surgery: a multicenter, retrospective cohort study.

Rachidi S, Li H, Wallace K, Li Z, Balch C, Lautenschlaeger T.

Platelets. 2019 Feb 11:1-9. doi: 10.1080/09537104.2019.1573977. [Epub ahead of print]

PMID:
30744463
4.

Predictors of Nodal and Metastatic Failure in Early Stage Non-small-cell Lung Cancer After Stereotactic Body Radiation Therapy.

Cerra-Franco A, Liu S, Azar M, Shiue K, Freije S, Hinton J, Deig CR, Edwards D, Estabrook NC 3rd, Ellsworth SG, Huang K, Diab K, Langer MP, Zellars R, Kong FM, Wan J, Lautenschlaeger T.

Clin Lung Cancer. 2019 May;20(3):186-193.e3. doi: 10.1016/j.cllc.2018.12.016. Epub 2018 Dec 29.

PMID:
30711394
5.

Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.

Coen JJ, Zhang P, Saylor PJ, Lee CT, Wu CL, Parker W, Lautenschlaeger T, Zietman AL, Efstathiou JA, Jani AB, Kucuk O, Souhami L, Rodgers JP, Sandler HM, Shipley WU.

J Clin Oncol. 2019 Jan 1;37(1):44-51. doi: 10.1200/JCO.18.00537. Epub 2018 Nov 15.

6.

Superior vena cava syndrome in a patient with locally advanced lung cancer with good response to definitive chemoradiation: a case report.

Hinton J, Cerra-Franco A, Shiue K, Shea L, Aaron V, Billows G, Al-Hader A, Lautenschlaeger T.

J Med Case Rep. 2018 Oct 20;12(1):301. doi: 10.1186/s13256-018-1843-4.

7.

Dihydrochalcone Glucosides from the Subaerial Parts of Thonningia sanguinea and Their in Vitro PTP1B Inhibitory Activities.

Pompermaier L, Heiss EH, Alilou M, Mayr F, Monizi M, Lautenschlaeger T, Schuster D, Schwaiger S, Stuppner H.

J Nat Prod. 2018 Sep 28;81(9):2091-2100. doi: 10.1021/acs.jnatprod.8b00450. Epub 2018 Sep 12.

PMID:
30207720
8.

The dosimetric differences in calculating lung SBRT plans on different image data sets: Comparison of the free breathing scan to both the average intensity projection scan and to the sum of calculations on each respiratory phase of the 4DCT scan.

Gaetani Liseo F, Lautenschlaeger T, Ewing M, Langer M.

Med Dosim. 2018 Aug 7. pii: S0958-3947(18)30083-9. doi: 10.1016/j.meddos.2018.06.003. [Epub ahead of print]

PMID:
30097226
9.

Toxicity of Radiosurgery for Brainstem Metastases.

Patel A, Dong T, Ansari S, Cohen-Gadol A, Watson GA, Moraes FY, Nakamura M, Murovic J, Chang SD, Hatiboglu MA, Chung C, Miller JC, Lautenschlaeger T.

World Neurosurg. 2018 Nov;119:e757-e764. doi: 10.1016/j.wneu.2018.07.263. Epub 2018 Aug 8. Review.

PMID:
30096494
10.

Chemoradiotherapy versus chemotherapy alone for unresected intrahepatic cholangiocarcinoma: practice patterns and outcomes from the national cancer data base.

Verma V, Kusi Appiah A, Lautenschlaeger T, Adeberg S, Simone CB 2nd, Lin C.

J Gastrointest Oncol. 2018 Jun;9(3):527-535. doi: 10.21037/jgo.2018.01.15.

11.

Histology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy.

Shiue K, Cerra-Franco A, Shapiro R, Estabrook N, Mannina EM, Deig CR, Althouse S, Liu S, Wan J, Zang Y, Agrawal N, Ioannides P, Liu Y, Zhang C, DesRosiers C, Bartlett G, Ewing M, Langer MP, Watson G, Zellars R, Kong FM, Lautenschlaeger T.

J Thorac Oncol. 2018 Oct;13(10):1549-1559. doi: 10.1016/j.jtho.2018.06.007. Epub 2018 Jun 27.

PMID:
29959060
12.

TERT Promoter Mutation Detection in Cell-Free Tumor-Derived DNA in Patients with IDH Wild-Type Glioblastomas: A Pilot Prospective Study.

Juratli TA, Stasik S, Zolal A, Schuster C, Richter S, Daubner D, Juratli MA, Thowe R, Hennig S, Makina M, Meinhardt M, Lautenschlaeger T, Schackert G, Krex D, Thiede C.

Clin Cancer Res. 2018 Nov 1;24(21):5282-5291. doi: 10.1158/1078-0432.CCR-17-3717. Epub 2018 Jun 25.

PMID:
29941484
13.

In Vitro Cell-free DNA Quantification: A Novel Method to Accurately Quantify Cell Survival after Irradiation.

Deig CR, Thowe RT, Frye ED, Chin-Sinex HJ, Mendonca MS, Lautenschlaeger T.

Radiat Res. 2018 Jul;190(1):22-27. doi: 10.1667/RR15016.1. Epub 2018 May 29.

PMID:
29813005
14.

Effects of Proton Center Closure on Pediatric Case Volume and Resident Education at an Academic Cancer Center.

Galle JO, Long DE, Lautenschlaeger T, Zellars RC, Watson GA, Ellsworth SG.

Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):710-718. doi: 10.1016/j.ijrobp.2017.10.055. Epub 2017 Nov 8.

PMID:
29413283
15.

Concurrent brain radiotherapy and EGFR-TKI may improve intracranial metastases control in non-small cell lung cancer and have survival benefit in patients with low DS-GPA score.

Liu Y, Deng L, Zhou X, Gong Y, Xu Y, Zhou L, Wan J, Zou B, Wang Y, Zhu J, Ding Z, Peng F, Huang M, Ren L, Lautenschlaeger T, Kong FS, Lu Y.

Oncotarget. 2017 Nov 30;8(67):111309-111317. doi: 10.18632/oncotarget.22785. eCollection 2017 Dec 19.

16.

Postdiagnosis aspirin use and overall survival in patients with melanoma.

Rachidi S, Wallace K, Li H, Lautenschlaeger T, Li Z.

J Am Acad Dermatol. 2018 May;78(5):949-956.e1. doi: 10.1016/j.jaad.2017.12.076. Epub 2018 Jan 6.

PMID:
29317280
17.

Brainstem metastases treated with Gamma Knife stereotactic radiosurgery: the Indiana University Health experience.

Patel A, Mohammadi H, Dong T, Shiue KR, Frye D, Le Y, Ansari S, Watson GA, Miller JC, Lautenschlaeger T.

CNS Oncol. 2018 Jan;7(1):15-23. doi: 10.2217/cns-2017-0029. Epub 2017 Dec 14.

18.

Blood-based biomarkers for precision medicine in lung cancer: precision radiation therapy.

De Ruysscher D, Jin J, Lautenschlaeger T, She JX, Liao Z, Kong FS.

Transl Lung Cancer Res. 2017 Dec;6(6):661-669. doi: 10.21037/tlcr.2017.09.12. Review.

19.

Blood-Based Nucleic Acid Biomarkers as a Potential Tool to Determine Radiation Therapy Response in Non-Small Cell Lung Cancer.

Deig CR, Mendonca MS, Lautenschlaeger T.

Radiat Res. 2017 Mar;187(3):333-338. doi: 10.1667/RR14613.1. Epub 2017 Feb 10. Review.

PMID:
28186469
20.

Undetected lymph node metastases in presumed early stage NSCLC SABR patients.

Cerra-Franco A, Diab K, Lautenschlaeger T.

Expert Rev Anticancer Ther. 2016 Aug;16(8):869-75. doi: 10.1080/14737140.2016.1199279. Epub 2016 Jun 20. Review.

PMID:
27279087
21.

MicroRNAs in non-small cell lung cancer invasion and metastasis: from the perspective of the radiation oncologist.

Verma V, Lautenschlaeger T.

Expert Rev Anticancer Ther. 2016 Jul;16(7):767-74. doi: 10.1080/14737140.2016.1191950. Epub 2016 Jun 1. Review.

PMID:
27215143
22.

International Medical Graduates in Radiation Oncology: Historical Trends and Comparison With Other Medical Specialties.

Verma V, Shah C, Lautenschlaeger T, Lin C, Beriwal S, Zhen W, Mehta MP, Zietman AL.

Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1102-6. doi: 10.1016/j.ijrobp.2016.03.008. Epub 2016 Mar 18.

PMID:
27209507
23.

Methionine and Kynurenine Activate Oncogenic Kinases in Glioblastoma, and Methionine Deprivation Compromises Proliferation.

Palanichamy K, Thirumoorthy K, Kanji S, Gordon N, Singh R, Jacob JR, Sebastian N, Litzenberg KT, Patel D, Bassett E, Ramasubramanian B, Lautenschlaeger T, Fischer SM, Ray-Chaudhury A, Chakravarti A.

Clin Cancer Res. 2016 Jul 15;22(14):3513-23. doi: 10.1158/1078-0432.CCR-15-2308. Epub 2016 Mar 2.

24.

Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.

Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, Goldberg S, Beal K, Yu JB, Kavanagh BD, Chiang VL, Camidge DR, Contessa JN.

J Clin Oncol. 2016 Jan 10;34(2):123-9. doi: 10.1200/JCO.2015.62.0138. Epub 2015 Oct 5.

25.

MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer.

Cui R, Meng W, Sun HL, Kim T, Ye Z, Fassan M, Jeon YJ, Li B, Vicentini C, Peng Y, Lee TJ, Luo Z, Liu L, Xu D, Tili E, Jin V, Middleton J, Chakravarti A, Lautenschlaeger T, Croce CM.

Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):E4288-97. doi: 10.1073/pnas.1502068112. Epub 2015 Jul 17.

26.

Is there pseudoprogression in secondary glioblastomas?

Juratli TA, Engellandt K, Lautenschlaeger T, Geiger KD, von Kummer R, Cerhova J, Chakravarti A, Krex D, Schackert G.

Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):1094-9. doi: 10.1016/j.ijrobp.2013.09.036.

27.

In vitro study of combined cilengitide and radiation treatment in breast cancer cell lines.

Lautenschlaeger T, Perry J, Peereboom D, Li B, Ibrahim A, Huebner A, Meng W, White J, Chakravarti A.

Radiat Oncol. 2013 Oct 23;8:246. doi: 10.1186/1748-717X-8-246.

28.

MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma.

Meng W, Ye Z, Cui R, Perry J, Dedousi-Huebner V, Huebner A, Wang Y, Li B, Volinia S, Nakanishi H, Kim T, Suh SS, Ayers LW, Ross P, Croce CM, Chakravarti A, Jin VX, Lautenschlaeger T.

Clin Cancer Res. 2013 Oct 1;19(19):5423-33. doi: 10.1158/1078-0432.CCR-13-0320. Epub 2013 Aug 14.

29.

Bladder preservation therapy for muscle-invading bladder cancers on Radiation Therapy Oncology Group trials 8802, 8903, 9506, and 9706: vascular endothelial growth factor B overexpression predicts for increased distant metastasis and shorter survival.

Lautenschlaeger T, George A, Klimowicz AC, Efstathiou JA, Wu CL, Sandler H, Shipley WU, Tester WJ, Hagan MP, Magliocco AM, Chakravarti A.

Oncologist. 2013 Jun;18(6):685-6. doi: 10.1634/theoncologist.2012-0461. Epub 2013 May 31.

30.

Predictors of biomarkers guiding targeted therapeutic strategies in locally advanced lung cancer.

Cottini F, Lautenschlaeger T.

Cancer J. 2013 May-Jun;19(3):263-71. doi: 10.1097/PPO.0b013e318297216a. Review.

PMID:
23708073
31.

Comparison of microRNA deep sequencing of matched formalin-fixed paraffin-embedded and fresh frozen cancer tissues.

Meng W, McElroy JP, Volinia S, Palatini J, Warner S, Ayers LW, Palanichamy K, Chakravarti A, Lautenschlaeger T.

PLoS One. 2013 May 16;8(5):e64393. doi: 10.1371/journal.pone.0064393. Print 2013.

32.

RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients.

Chakravarti A, Wang M, Robins HI, Lautenschlaeger T, Curran WJ, Brachman DG, Schultz CJ, Choucair A, Dolled-Filhart M, Christiansen J, Gustavson M, Molinaro A, Mischel P, Dicker AP, Bredel M, Mehta M.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1206-11. doi: 10.1016/j.ijrobp.2012.10.008. Epub 2012 Nov 22.

33.

Combined RASSF1A and RASSF2A Promoter Methylation Analysis as Diagnostic Biomarker for Bladder Cancer.

Meng W, Huebner A, Shabsigh A, Chakravarti A, Lautenschlaeger T.

Mol Biol Int. 2012;2012:701814. doi: 10.1155/2012/701814. Epub 2012 Mar 11.

34.

Technological advances in radiation oncology for central nervous system tumors.

Noda SE, Lautenschlaeger T, Siedow MR, Patel DR, El-Jawahri A, Suzuki Y, Loeffler JS, Bussiere MR, Chakravarti A.

Semin Radiat Oncol. 2009 Jul;19(3):179-86. doi: 10.1016/j.semradonc.2009.02.006.

PMID:
19464633
35.

Molecular advances of brain tumors in radiation oncology.

Noda SE, El-Jawahri A, Patel D, Lautenschlaeger T, Siedow M, Chakravarti A.

Semin Radiat Oncol. 2009 Jul;19(3):171-8. doi: 10.1016/j.semradonc.2009.02.005. Review.

PMID:
19464632

Supplemental Content

Loading ...
Support Center